Znanstveni rad - Pregledni rad
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Frontiers in Pharmacology, 12 (2021); 678546. https://doi.org/10.3389/fphar.2021.678546

Roguljic, Hrvoje; Nincevic, Vjera; Bojanic, Kristina; Kuna, Lucija; Smolic, Robert; Vcev, Aleksandar; Primorac, Dragan; Vceva, Andrijana; Wu, George Y.; Smolic, Martina

Citirajte ovaj rad

Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A. ... Smolic, M. (2021). Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology, 12.. doi: 10.3389/fphar.2021.678546

Roguljic, Hrvoje, et al. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology, vol. 12, 2021. https://doi.org/10.3389/fphar.2021.678546

Roguljic, Hrvoje, Vjera Nincevic, Kristina Bojanic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, Dragan Primorac, Andrijana Vceva, George Y. Wu i Martina Smolic. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology 12 (2021). https://doi.org/10.3389/fphar.2021.678546

Roguljic, H., et al. (2021) 'Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update', Frontiers in Pharmacology, 12. doi: 10.3389/fphar.2021.678546

Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, i sur.. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology [Internet]. 2021. [pristupljeno 01.10.2024.];12. doi: 10.3389/fphar.2021.678546

H. Roguljic, et al., "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update", Frontiers in Pharmacology, vol. 12, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:396498. [Citirano: 01.10.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.